370例接受依鲁替尼治疗的套细胞淋巴瘤患者结局:三项开放标签研究的汇总分析
该汇总分析纳入370例接受依鲁替尼治疗的复发/难治套细胞淋巴瘤患者,客观缓解率为66%(完全缓解20%,部分缓解46%),中位缓解持续时间、无进展生存期和总生存期分别为18.6、12.8和25.0个月。多因素分析显示ECOG体能状态、简化MCL国际预后指数评分、巨块型病变和母细胞样组织学影响生存。
要点
- 复发/难治套细胞淋巴瘤患者接受依鲁替尼的客观缓解率为66%,完全缓解率20%。
- 中位缓解持续时间18.6个月,中位无进展生存期12.8个月,中位总生存期25.0个月。
- ECOG体能状态、sMIPI评分、巨块型病变和母细胞样组织学与总生存期和无进展生存期相关。
核心结论
- 依鲁替尼在复发/难治套细胞淋巴瘤中高度活跃,患者结局与基线特征及疾病生物学演变相关。
研究设计与样本
- 汇总三项开放标签研究的370例复发/难治套细胞淋巴瘤患者,均接受依鲁替尼治疗。
主要发现
- 客观缓解率为66%(完全缓解20%,部分缓解46%),中位缓解持续时间18.6个月,中位无进展生存期12.8个月,中位总生存期25.0个月。
- 单因素分析显示,既往治疗线数为1线与>1线的患者相比总生存期更长。
- 多因素分析显示,既往治疗线数为1线影响无进展生存期;ECOG体能状态、sMIPI评分、巨块型病变和母细胞样组织学影响总生存期和无进展生存期。
- 母细胞样组织学患者与非母细胞样组织学患者至最佳缓解时间相似,但客观缓解率、缓解持续时间、无进展生存期和总生存期更低。
- sMIPI评分较好、ECOG体能状态0-1、非巨块型病变和非母细胞样组织学患者的无进展生存期和总生存期更长。
关键数值与推荐
- 客观缓解率66%,完全缓解20%,部分缓解46%。
- 中位缓解持续时间18.6个月,中位无进展生存期12.8个月,中位总生存期25.0个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib is highly active in treating mantle cell lymphoma (MCL), an aggressive B-cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory MCL (n = 370) treated with ibrutinib had an objective response rate (ORR) of 66% (20% complete response; 46% partial response); median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were 18·6, 12·8 and 25·0 months, respectively. Univariate analyses showed patients with one versus >one prior line of therapy had longer OS. Multivariate analyses identified that one prior line of therapy affected PFS; Eastern Cooperative Oncology Group (ECOG) performance status, simplified MCL international prognostic index (sMIPI) score, bulky disease, and blastoid histology affected OS and PFS. Patients with blastoid versus non-blastoid histology had similar time to best response, but lower ORR, DOR, PFS and OS. OS and PFS were longer in patients with better sMIPI, patients with ECOG performance status 0-1, non-bulky disease and non-blastoid histology. Additionally, the proportion of patients with poor prognostic factors increased with increasing lines of therapy. Together, results suggest that patient outcomes following treatment failure with ibrutinib are related to the natural biological evolution of the disease.
引用
- Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017. PMID: 28832957. doi:10.1111/bjh.14870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。